Alliances
The UK’s Wellcome Trust, a charitable foundation, announced it is creating the $330 million Leap Fund to invest in high-risk healthcare and life science research.
BioNTech AG and Genevant Sciences entered into a strategic partnership to develop five therapeutics to treat rare diseases.
Shares of MabVax Therapeutics have more than doubled this morning after Boehringer Ingelheim inked a deal to acquire the rights to an antibody development program that will be used to target multiple solid tumors.
Axovant, one of Vivek Ramaswamy’s biotech companies best known for its catastrophic Alzheimer’s failure in September 2017, is replenishing its pipeline with a licensing deal with Australian company Benitec Biopharma.
Shares of Aveo are falling this morning after the company revealed Novartis has walked away from its development deal for the company’s proprietary antibody AV-380, as well as other antibodies that inhibit Growth Differentiation Factor 15.
TRIGR Therapeutics, based in Irvine California, signed a deal with South Korean company ABL Bio Corporation. TIRGR is licensing the global commercial rights to ABL Bio’s pipeline of antibodies to treat cancer.
Athenex is kicking off the second half of 2018 with a bang. The company secured $100 million in investments from Perceptive Advisors, is making major inroads in China with a joint venture with Chinese biotech Xiangxue Life Sciences and an in-licensing agreement from Avalon PolyTom Limited.
U.S. District Judge in Philadelphia came down on the side of the Federal Trade Commission (FTC) in an anti-trust lawsuit filed in 2014 against AbbVie and its partner Besins Healthcare. They are ordered to pay $448 million.
Shares of Galapagos NV fell more than 15 percent Thursday afternoon and continued to fall in premarket trading after the Belgium-based company said AbbVie opted to walk away from its cystic fibrosis collaboration.
Acceleron Pharma plans to seek regulatory approval next year for its investigational drug luspatercept. The treatment hit its Phase III endpoints.
PRESS RELEASES